Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep595 | Endocrine tumours and neoplasia | ECE2016

Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients

Arlien-Soborg Mai C. , Alvarson Elin , Dal Jakob , Jorgensen Jens Otto L.

Context: The nadir serum GH level during glucose suppression (OGTT) is recommended in patients treated by surgery, but not during SA treatment. We have shown that patients considered controlled by SA don’t suppress serum GH during OGTT and have impaired disease-specific QoL as compared to patients controlled by surgery. We hypothesize SA treated patients also don’t suppress GH in response to mixed meals.Aim: To compare GH levels during two mixe...

ea0035p673 | Growth hormone IGF axis basic | ECE2014

Incidence and late prognosis of acromegaly in Denmark: preliminary data

Dal Jakob , Feldt-Rasmussen Ulla , Andersen Marianne , Kristensen Lars , Laurberg Peter , Sorensen Henrik , Jorgensen Jens Otto

Introduction: Acromegaly is a rare disease caused by GH hypersecretion from a pituitary adenoma. However, accurate estimates of incidence and prevalence are scarce and not based on nationwide populations. It is well known that surgical cure may normalize mortality and improve morbidity but similar data are not available for patients receiving medical treatment.Method: We first validated the ICD-8 and ICD-10 diagnosis codes for acromegaly in The National ...

ea0056gp190 | Pituitary / Growth Hormone ' IGF Axis | ECE2018

Insulin sensitivity improves after disease control in acromegaly irrespective of treatment modality and despite an increase in intrahepatic lipid content: data from an investigator-initiated prospective trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Jessen Niels , Jorgensen Jens Otto Lunde

Background: Active acromegaly induces insulin resistance despite a lean phenotype, both of which reverse by curative surgery. The impact of somatostatin analogue treatment on insulin sensitivity is less certain and may be offset by its anti-lipogenic effects.Aim: To study insulin sensitivity, body composition and extopic lipid content in newly diagnosed patients with acromegaly before and ≥6 months after successful surgical or medical treatment.</p...

ea0081p512 | Late-Breaking | ECE2022

Changes in acromegaly presentation and treatment over a three-decade period

Aagaard Charlotte , S Christophersen Amanda , Finnerup Susanne , Rosendal Christian , Vestergaard Peter , Karmisholt Jesper , H Nielsen Eigil , Dal Jakob

Objective: To study time-dependent changes in the prevalence and patient characteristics of acromegaly, as well as to access the impact of changes in treatment on disease control.Methods: A total of 107 patients with acromegaly were identified by healthcare registries and subsequently validated by patient chart review over a three-decade period (1992-2021).Results: The prevalence of acromegaly significantly increased throughout the...

ea0063oc3.4 | Cushing's and acromegaly | ECE2019

Restoration of basal glucose turnover after disease control in acromegaly depends on treatment modality: a prospective, investigator-initiated trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Hjelholt Astrid , Jessen Niels , Moller Niels , Otto Lunde Jorgensen Jens

Background: Growth Hormone (GH) reversibly suppresses insulin-stimulated glucose uptake in skeletal muscle, but less is known about GH effects on glucose metabolism in the basal state. Somatostatin suppresses GH as well as insulin, and may also exert direct effects in skeletal muscle. This may have therapeutic implications in the treatment of acromegalic patients with a somatostatin analogue (SA).Aim: To study basal and insulin-stimulated glucose metabol...

ea0070aep777 | Pituitary and Neuroendocrinology | ECE2020

Acromegaly is associated with reduced socioeconomic status and more so in female patients: A nationwide population-based study

Dal Jakob , Nielsen Eigil H , Feldt-Rasmussen Ulla , Andersen Marianne , Feltoft Claus , Vestergaard Peter , Stochholm Kirstine , Otto Jorgensen Jens

Context: Acromegaly is a rare and insidious disease associated with severe somatic morbidity but data on socioeconomic status are scarce.Objective: To study the socioeconomic status in acromegaly in a population based, nationwide follow-up study.Patients and Methods: All incident cases of acromegaly (n = 576) during the period 1997–2010 were included, representing 10.116 years at risk. For every patient, 100 pers...

ea0081p144 | Pituitary and Neuroendocrinology | ECE2022

Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in active acromegaly

Maria Falch Camilla , Arlien-Soborg Mai C. , Dal Jakob , Sundaram Arvind , Michelsen Annika E. , Ueland Thor , Olsen Linn G. , Heck Ansgar , Bollerslev Jens , Jorgensen Jens Otto , Olarescu Cristina

Objective: Patients with acromegaly present increased insulin resistance despite reduced adipose tissue (AT) mass. Growth hormone (GH) stimulates lipolysis, but the role of AT as a metabolic factor in patients with acromegaly is still uncertain. Moreover, there is a need for better biomarkers of disease activity in acromegaly.Methods: RNA-sequencing was performed on paired subcutaneous AT (SAT) biopsies from patients (n=6) with active acromegaly...

ea0081p657 | Pituitary and Neuroendocrinology | ECE2022

Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment

C. Arlien-Soborg Mai , Alle Madsen Michael , Dal Jakob , Krusenstjerna-Hafstrom Thomas , Ringgaard Steffen , Skou Nickolaj , Lyng Hogild Morten , Otto Jorgensen Jens

Background: Insulin resistance as part of the metabolic syndrome is associated with ectopic lipid deposition. Growth hormone (GH) status also modulates ectopic lipid accumulation but how this associates with insulin resistance in patients with GH disorders is not well established.Aim: To study body composition, ectopic lipid deposition and insulin sensitivity in acromegaly and adult GH-deficiency before and after treatment.Subjects...

ea0049gp181 | Pituitary | ECE2017

Targeting either GH or IGF-I levels during somatostatin analogue treatment in patients with acromegaly: A randomized, investigator-initiated multicenter study

Dal Jakob , Klose Marianne , Heck Ansgar , Andersen Marianne , Kistorp Caroline , Nielsen Eigil Husted , Bollerslev Jens , Feldt-Rasmussen Ulla , Jorgensen Jens Otto Lunde

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...

ea0041oc13.2 | Pituitary Clinical | ECE2016

Growth hormone and insulin signalling after acute GH exposure in patients with controlled acromegaly: impact of surgery versus somatostatin analog treatment

Dal Jakob , Lundby Hoyer Katrine , Pedersen Steen B , Magnusson Nils , Bjerrring Peter , Frystyk Jan , Moller Niels , Jessen Niels , Jorgensen Jens Otto L

Background: Somatostatin analogue treatment (SA) is used in acromegaly to suppress GH secretion and tumour growth. In addition, SA also suppresses insulin secretion and may impact on GH signalling in peripheral tissues.Objective: To compare GH and insulin signalling in skeletal muscle and adipose tissue in vivo before and after a single exogenous GH bolus in patients with acromegaly controlled by either surgery alone or by ongoing treatment with a slow-r...